Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Centus Biotherapeutics
Centus Biotherapeutics
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Equidacent
Bevacizumab
2020-09-24
Renal cell carcinoma
,
Colorectal neoplasms
,
Breast neoplasms
,
Ovarian neoplasms
,
Non-small-cell lung carcinoma
,
Glioblastoma
,
Fallopian tube neoplasms
,
Kidney neoplasms
,
Uterine cervical neoplasms
,
Peritoneal neoplasms
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Bevacizumab
healthy volunteers/patients
,
colorectal neoplasms
,
non-small-cell lung carcinoma
,
lung neoplasms
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use